secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mersana Therapeutics, Inc. (—)
CIK:        0001442836
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0001104659-25-070245
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mersana Therapeutics to effect 1-for-25 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse stock split ratio set at 1-for-25; effective July 25, 2025 at 5:00 p.m. ET.
- No fractional shares issued; stockholders receive cash in lieu of fractional shares.
- Common stock begins trading on split-adjusted basis July 28, 2025 under ticker MRSN.
- Authorized shares unchanged; proportionate adjustments made to equity awards and plans.
- Split intended to bring company into compliance with Nasdaq minimum bid price requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1442836/000110465925070245/0001104659-25-070245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1442836/000110465925070245/tm2521489d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-070245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer